On January 1, 2024, AlloVir Board Approved Reduction Its Workforce By Approximately 95% Of Current Employee Base To Reduce Costs And Preserve Capital - Filing
On January 1, 2024, AlloVir Board Approved Reduction Its Workforce By Approximately 95% Of Current Employee Base To Reduce Costs And Preserve Capital - Filing
The move follows AlloVir's announcement on December 22, 2023 that it is discontinuing its three global Phase 3 posoleucel studies. This workforce reduction will take place primarily during the first quarter of 2024 and expects to be substantially completed by April 15, 2024. As a result of these actions, AlloVir expects to incur personnel-related restructuring charges of approximately $13 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the first quarter of 2024.
此舉是在AlloVir於2023年12月22日宣佈停止其三項全球3期posoleucel研究之後採取的。裁員將主要在2024年第一季度進行，預計將在2024年4月15日之前基本完成。由於這些行動，AlloVir預計將產生約1300萬美元的人事相關重組費用，這些費用與一次性員工解僱現金支出有關，包括遣散費和其他福利，預計這些支出將在2024年第一季度大量產生。